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Abstract
Background: Activation of embryonic signaling pathways quiescent in the adult pancreas is a feature of pancreatic cancer
(PC). These discoveries have led to the development of novel inhibitors of pathways such as Notch and Hedgehog signaling
that are currently in early phase clinical trials in the treatment of several cancer types. Retinoid signaling is also essential for
pancreatic development, and retinoid therapy is used successfully in other malignancies such as leukemia, but little is
known concerning retinoid signaling in PC.
Methodology/Principal Findings: We investigated the role of retinoid signaling in vitro and in vivo in normal pancreas,
pancreatic injury, regeneration and cancer. Retinoid signaling is active in occasional cells in the adult pancreas but is
markedly augmented throughout the parenchyma during injury and regeneration. Both chemically induced and genetically
engineered mouse models of PC exhibit a lack of retinoid signaling activity compared to normal pancreas. As a
consequence, we investigated Cellular Retinoid Binding Protein 1 (CRBP1), a key regulator of retinoid signaling known to
play a role in breast cancer development, as a potential therapeutic target. Loss, or significant downregulation of CRBP1 was
present in 70% of human PC, and was evident in the very earliest precursor lesions (PanIN-1A). However, in vitro gain and
loss of function studies and CRBP1 knockout mice suggested that loss of CRBP1 expression alone was not sufficient to
induce carcinogenesis or to alter PC sensitivity to retinoid based therapies.
Conclusions/Significance: In conclusion, retinoid signalling appears to play a role in pancreatic regeneration and
carcinogenesis, but unlike breast cancer, it is not mediated directly by CRBP1.
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Introduction
Increasing evidence supports a pivotal role for developmental
signaling pathways such as Notch [1] and Hedgehog [2,3,4] in
pancreatic cancer, with inhibitors of these pathways currently in
early phase clinical trials. Notch and hedgehog are also involved in
pancreatic injury, regeneration and repair [5], conditions that are
known to predispose to cancer. Retinoid signaling is vital for
embryonic pancreas formation [6,7,8], but little is known about its
potential role in pancreatic cancer.
Retinoids are naturally occurring or synthetic Vitamin A
analogues, which have been used successfully in the treatment of
acute promyelocytic leukaemia (APL) [9]. Despite the success of
retinoid treatment in APL, treatment of solid tumors has met with
limited success [10,11], and some evidence suggests that this
resistance to retinoid therapy may be due to aberrations in retinoid
signaling. Downregulation of retinoid receptors has been reported
in many cancers, such as breast, lung, prostate and esophageal
cancer [11], and downregulation of upstream components
involved in retinoid metabolism and storage are emerging as
possible key regulators of carcinogenesis and contributors to
resistance to retinoid based therapies.
Cellular Retinoid Binding protein 1 (CRBP1) plays a major role
in retinoid signaling and downregulation of CRBP1 expression
occurs in breast [12], prostate [13], gastric [14] and ovarian [15]
cancers. Loss of CRBP1 expression in breast epithelium leads to
loss of differentiation and tumour progression by interfering with
retinoid storage and its metabolism to the active metabolite,
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Retinoic Acid, producing a localised retinoid deficiency [16], with
altered retinoid responsiveness [17] and cellular transformation.
Pancreatic cancer (PC) is the fourth leading cause of cancer
death in Western societies with an overall 5-year survival rate of
less than 5% [18]. Advances in neoadjuvant and adjuvant
chemotherapeutic regimens have resulted in some improvement
in outcomes, but pancreatectomy remains the single most effective
treatment modality for PC, and offers the only potential for cure.
Only 20% of patients present with localised, non-metastatic
disease which is suitable for resection [19]. Those who undergo
resection and receive adjuvant therapy have a median survival of
12–22 months and a 5-year survival of 20–25% [20]. Existing
systemic therapies are only modestly effective and the median
survival for patients with metastatic disease remains 6 months.
Consequently there is a great need to develop novel therapeutic
strategies for pancreatic cancer.
Here we identify a potential role for retinoid signaling in
pancreatic cancer and pancreatic regeneration and as a conse-
quence may constitute a targetable mechanism for the develop-
ment of novel therapeutic strategies. Loss of CRBP1, a key
regulator of retinoid signalling and important in breast cancer,
although frequent in PC, unlike breast cancer was not itself
sufficient to induce transformation.
Methods
Ethics Statement
Ethical approval for animal experimentation was obtained from
the Garvan Institute Animal Ethics Committee (Approval
numbers 09/53; 07/10). Multicentre ethical approval was
obtained from the Human Research Ethics Committees from
University teaching hospitals: Westmead Hospital, Concord
Hospital, Royal Prince Alfred Hospital and St Vincent’s Hospital
Campus in Sydney for the acquisition of fresh and archival tissue
and recording of clinicopathological data for patients with the
diagnosis of pancreatic cancer. Informed written consent was
obtained from all patients.
RARE-LacZ mice
RARE-LacZ mice contain a LacZ transgene controlled by a
retinoic acid response element (RARE). Cells with active RA
signalling stain positive for b-galactosidase (b-gal). Untreated
animals (n = 8) were sacrificed at 10–12 weeks of age and their
pancreas harvested for b-gal staining.
Murine Pancreatitis Model
A caerulein-induced model of chronic pancreatitis was used
similar to previous models [21]. Mice (n = 16) were treated with
repeated intra-peritoneal injections of caerulein (MP Biomedicals,
Solon, OH) five times a day, twice a week for 10 weeks. In this
model complete acinar cell regeneration is reported to occur by 6
weeks after cessation of caerulein treatment. Therefore mice were
sacrificed at 0, 2, 4 and 6 weeks after the cessation of caerulein
injections and their pancreas harvested in order to investigate RA
signalling at various time points during the recovery period.
Murine Pancreatic Cancer Models
RARE-LacZ mice (n = 10) 10 weeks of age were treated with
7,12-dimethylbenzanthracene (DMBA; Sigma-Aldrich, St Louis,
MO) as previously described [22]. Mice were sacrificed when they
demonstrated signs of illness or 9 months post-DMBA treatment
and tissue collected for b-gal staining.
LSL-KrasG12D/+, LSL-Trp53R172H/+, and Pdx1-Cre mice were
obtained from the Mouse Models of Human Cancer Consortium at
the National Cancer Institute (Frederick, MD). To generate
pancreatic tumours in which RA signalling activity could be assessed
RARE-LacZ mice were crossed with LSL-KrasG12D/+;LSL-
Trp53R172H/+;Pdx1-Cre mice to generate LSL-KrasG12D/+;LSL-
Trp53R172H/+;Pdx1-Cre;RARE-LacZ offspring (n=8). Quadruple
transgenic mice were left to age until tumours formed at which point
they were euthanised and tissue was collected for b-gal staining.
b-galactosidase staining
4 mm pancreatic sections were de-waxed and rehydrated before
unmasking was achieved using target-retrieval solution (S2367,
pH 9.0: DAKO Corporation, Carpenteria, CA) in a boiling water
bath for 20 minutes. Endogenous peroxidase activity was
quenched with 3% hydrogen peroxide in methanol. Sections were
incubated for 1 hour with 1:50 anti-b-galactosidase (AB616)
polyclonal rabbit antibody (Abcam, Cambridge, UK). A labelled
polymer horseradish peroxidase anti-rabbit detection system was
used according to the manufacturer’s instructions (Envision+ anti-
rabbit; DAKO Corporation, CA). 3,39-diaminobenzidine was used
as a substrate. Counter-staining was performed with Mayer’s
hematoxylin (DAKO Corporation, Carpenteria, CA).
Patient Cohort
We identified a cohort of 90 patients who underwent pancreatic
resection or biopsy from these hospitals. This cohort represents a
subset of a previously described group of 348 patients [23,24].
CRBP1 Immunohistochemistry
Pancreatic tissue micro-arrays (4 mm sections) were de-waxed
and rehydrated before unmasking was achieved using target-
retrieval solution (S1699, pH 6.0: DAKO Corporation, Carpen-
teria, CA) in a pressure cooker for 5 minutes. Endogenous
peroxidase activity was quenched with 3% hydrogen peroxide in
methanol. Sections were incubated for 1 hour with 1:50 anti-
CRBP1 (FL-135) polyclonal rabbit antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA). A labelled polymer horseradish
peroxidase anti-rabbit detection system was used according to
the manufacturer’s instructions (Envision+ anti-rabbit; DAKO
Corporation, Carpenteria, CA). 3,39-diaminobenzidine was used
as a substrate. Counter-staining was performed with Mayer’s
hematoxylin (DAKO Corporation, Carpenteria, CA).
Up to three separate samples of pancreas were examined per
patient. Staining was assessed by two separate observers for each case
(E.K.C. and S.A.O.). Standardisation of scoring was achieved by
comparison of scores between observers, and by conferencing, where
any discrepancies were resolved by consensus. Scores were given as a
percentage of cells with positive cytoplasmic staining within the
representative area of the tissue micro-array core, and the absolute
intensity of cytoplasmic staining on a scale of 0 to 3 (0 representing
no staining, 1 representing heterogenous cytoplasmic staining, 2
representing homogenous cytoplasmic staining, and 3 representing
intense homogenous cytoplasmic staining). A positive score for
CRBP1 was given based on the following criteria: .50% of cells
having homogeneous cytoplasmic staining, with an intensity of .1.
Survival analysis was performed using Kaplan-Meier analysis,
with differences in survival assessed using the Log-Rank test using
StatView 5.0 Software (Abacus Systems, Berkeley, CA).
Pancreatic Cell Lines
Six pancreatic cancer cell lines were used: AsPC-1, BxPC-3,
Capan-2, HPAC, MiaPaCa2 and PANC1 (ATCC, VA, USA).
These cell lines were cultured according to ATCC protocols.
Human Pancreatic Ductal Epithelial (HPDE and HPDE-EcoR)
Retinoid Signalling in PC
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cells were used as a normal control (kindly provided by Ming-
Sound-Tsao, Ontario Cancer Institute) and cultured as described
previously [25].
Western blotting
Protein extracts were visualised using 4–12% Bis-Tris precast
gels (Invitrogen, Victoria, Australia) and transferred to PVDF
membranes according to the manufacturer’s protocol. The filters
were blocked with 5% skim milk in TBST buffer. Anti-CRBP1
antibody (FL-135) was used at 1:500 overnight. Membranes were
then incubated with anti-rabbit immunoglobulin G (IgG) conju-
gated with horseradish peroxidase (1:2000) (Amersham, (GE
Healthcare), NSW, Australia) for 1 hour at room temperature
followed by enhanced chemiluminescence reagent (Perkin Elmer,
Waltham, MA).
RNA extraction and cDNA synthesis
RNA from pancreatic cell lines was extracted using TrizolH
Reagent (Invitrogen, Victoria, Australia) according to the
manufacturer’s instructions. cDNA was synthesised using AB-
geneH Reverse-ITTM RTase Blend (ABgene, Surrey, UK) with a
mix of Oligo dT and Random Hexamers using the First Strand
Synthesis Method. Following denaturation of the RNA at 70uC,
Reverse Transcription (RT) reactions were performed in a
thermocycler DNA engine DYADTM (MJ Research, Waltham,
MA) with the stepwise program of 25uC for 10 minutes, 35uC for
30 minutes, 47uC for 45 minutes, then 75uC for 10 minutes.
Quantitative Real-Time PCR (QPCR)
TaqManH gene expression assays (Applied Biosystems, Victoria,
Australia) of CRBP1 (Hs00161252_m1) were performed according
to the manufacturer’s instructions. GAPDH (4326317E, Taq-
ManH endogenous control) was used as an endogenous control.
TaqManH qPCR reactions were performed in triplicate using the
ABI Prism 7900HT Sequence Detection System (Applied
Biosystems, Victoria, Australia). Standard curves were included
to ensure the reactions were performed in the linear range and
were used to adjust the efficiency of the reaction. The cycling
conditions included initial denaturation step at 95uC for
4 minutes, followed by 95uC (30 seconds) and 72uC (30 seconds)
for 60 cycles.
Knockdown of CRBP1 in HPDE cells
Two short hairpin RNA (shRNA) constructs targeting CRBP1,
siCRBP1-A and siCRBP1-B as well as a scrambled control,
siCRBP1-scrambled, (kindly provided by Nicoletta Sacchi,
Roswell Park Cancer Institute, NY) were transfected into Phoenix
cells using FuGENE transfection reagent (Roche, NSW, Australia).
Retroviral supernatants were collected and used to infect HPDE-
EcoR cells. Puromycin (1 mg/mL) was used to select successfully
infected cells. Successful knockdown of CRBP1 was determined by
western blot.
3D culture of HPDE cells
HPDE-EcoR cells infected with shRNA were grown on
chamber slides coated with growth factor reduced matrigel (BD
Biosciences, San Hose, CA) in keratinocyte serum-free medium
(Invitrogen, Victoria, Australia) supplemented with epidermal
growth factor, bovine pituitary extract, 10% fetal calf serum and
2% matrigel for 20 days. Media was changed every 4 days. 3D
structures were recovered at 3, 7, 10, 15 and 20 days using BD cell
recovery solution (BD Biosciences, San Hose, CA) and protein
extracted for western blot.
Stable transfection of MiaPaCa2 cells
Four different clones of MiaPaCa2 cells expressing different
levels of CRBP1 (MP2CRBP1 cells) and their respective controls
were created to evaluate the effect of CRBP1 expression on
MiaPaCa2 cells. The cells were created using the pcDNATM6.2/
GFP plasmid (Invitrogen, Victoria, Australia) and the pQCXIP
plasmid (Clontech Laboratories, Mountain, View, CA) containing
the CRBP1 gene. The vectors were transfected using Amaxa
NucleofectorH Technology (Lonza Cologne AG, Cologne, Ger-
many) according to the manufacturer’s instructions. The cells
transfected with pcDNATM6.2/GFP plasmid were further sorted
for GFP expression using flow cytometry to enrich the population
of cells expressing GFP/CRBP1. The expression of CRBP1 in
each population was confirmed by western blot. The cells were
treated with 2, 5 or 10 mM of all-trans-retinoic acid (ATRA;
Sigma-Aldrich, St Louis, MA) on Day 1. The cells were harvested
and counted on Day 1, 2, 4 and 6 to measure cell proliferation.
DNA extraction
1 mm tissue cores were removed from formalin-fixed paraffin-
embedded human PC samples and DNA was extracted using the
Gentra Puregene Tissue Kit (Qiagen, Valencia, CA) according to
the manufacturer’s instructions. DNA from cell lines was extracted
using a DNA extraction kit (Stratagene, Santa Clara, CA)
according to the manufacturer’s instructions.
Bisulfite treatment
Bisulfite treatment was carried out using the previously
described methods [26] with minor modifications. In summary,
1 mg DNA was denatured by treatment with 0.3 M NaOH and
modified with 3 M sodium bisulfite for 6 hours. Modified DNA
was purified using QIAEX II Gel Extraction Kit (Qiagen,
Valencia, CA). Bisulfite treatment was completed by adding
5.5 ml of 3 M NaOH, precipitated with ethanol, and resuspended
in 50 ml of DNA Hydration Solution (Gentra Puregene Tissue
Kit, Qiagen, Valencia, CA).
Methylation specific PCR (MSP)
DNA methylation patterns in the CpG island of CRBP1 in
human pancreatic cell lines and human samples were determined
by MSP using previously published primers [26,27]. PCR
amplifications were performed in 12.5 ml reaction mixtures
containing 1 to 5 ml of bisulfite treated DNA, dNTPs (each at
200 mM), primers (0.4 mM each reaction), 1.5 mM MgCl2, 0.75
unit of AmpliTaq GoldH DNA polymerase (Applied Biosystems,
Victoria, Australia), and 16 PCR Buffer II (Applied Biosystems,
Victoria, Australia). MSP was carried out using the following
conditions: 95uC (30 seconds), 58uC (30 seconds), 72uC (30 sec-
onds) for 40 cycles. The cycling conditions included an initial
denaturation step at 95uC for 10 minutes and final elongation at
72uC for 10 minutes. All PCR products were visualised using
1.5% agarose gel. MYOD primers [28] were used as a control for
the quality of the bisulfite treated DNA. These primers contain no
CpG sequences.
5-AZA and TSA treatment
MiaPaCa2 cells were treated as follows: (1) Treated on Day 1
with 300 mM of 5-AZA-29deoxycytidine (5-AZA) (Sigma-Aldrich,
St Louis, MO) and harvested on Day 4; (2) Treated on Day 1 with
100 nM of Trichostatin A (TSA) (Sigma-Aldrich, St Louis, MO)
and harvested on Day 4; (3) Treated on Days 1 and 3 with TSA
and harvested on Day 4; (4) Treated on Day 1 with 5-AZA, Days 2
and 3 with TSA and harvested on Day 4; (5) Treated on Day 1
Retinoid Signalling in PC
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with 5-AZA, Days 2, 3 and 5 with TSA and harvested on Day 6.
Untreated MiaPaCa2 and HPDE cells were used as controls.
During treatment, the media was changed daily, and cells were
washed twice with cold PBS prior to nucleic acid and/or protein
extraction.
Results
Retinoid signaling in normal pancreas, pancreatic injury
and regeneration
Retinoic Acid Response Element (RARE-LacZ) reporter mice
that mark cells with active retinoid signaling [29] showed that in
normal pancreas, active retinoid signaling is restricted to the Islets
of Langerhans and rare single, or small clusters of exocrine cells
with an acinar or centro-acinar based on location and morphology
(Figure 1). Repeated intraperitoneal injections of the cholecysto-
kinin analogue caerulein [30] induces chronic pancreatitis in mice
with morphological changes such as loss of acinar cell mass and an
increase in pancreatic fibrosis similar to that seen in the human
condition. To investigate retinoid signalling in the setting of
pancreatic injury and regeneration, we induced pancreatitis in
RARE-LacZ mice. Mice were treated for 10 weeks with
intraperitoneal injections of caerulein, sacrificed upon cessation
of treatment, or allowed to recover for 2, 4 or 6 weeks. Mice
sacrificed immediately following the final injection of caerulein (at
the time of acute injury) had significantly smaller pancreata due to
acinar cell atrophy and fibrosis with the formation of ‘‘tubular
complexes’’, a manifestation of acinar to ductal metaplasia, the
earliest morphological changes associated with pancreatic carci-
nogenesis (Figure 2A) [31,32].
At 2 weeks following the cessation of caerulein treatment,
exocrine regeneration had commenced with an increase in acinar
cell mass, but with residual tubular complexes and a persisting
inflammatory infiltrate (Figure 2B). At 4 and 6 weeks, exocrine
pancreata had near fully, but not completely regenerated, with
occasional acinar units still displaying enlarged lumena and a
surrounding mild inflammatory infiltrate (Figures 2C and 2D). b-
galactosidase staining of pancreata from caerulein-treated RARE-
LacZ mice demonstrated increased retinoid signaling activity in a
large proportion of acinar cells immediately following cessation of
caerulein treatment (Figure 2E). Retinoid activity peaked at 2
weeks and diminished at 4 weeks with near normal levels at 6
weeks (Figures 2F, G, H).
Retinoid signalling in pancreatic cancer
To determine if retinoid signaling in the pancreas was altered
during carcinogenesis we investigated retinoid signaling activity in
chemically induced (DMBA) [22] and genetically engineered
mouse models of pancreatic cancer [33]. DMBA treated RARE-
LacZ mice developed poorly differentiated, sarcomatoid tumours
(Figure 3A) with a distinct absence of any cells that exhibited active
retinoid signalling despite examination of multiple sections
(Figure 3B). Pancreas specific promoter driven Cre recombinase
(Pdx1-Cre) induced expression of activated KRas and mutant p53
within the pancreas are currently the most appropriate genetically
engineered murine model of pancreatic cancer. These LSL-
KrasG12D/+/LSL-Trp53R172H/+/Pdx1-Cre mice develop pancre-
atic precursor lesions (PanIN) that progress to highly invasive and
metastatic pancreatic ductal adenocarcinoma at a median of 5
months [33]. These mice were crossed with RARE-LacZ reporter
mice to generate LSL-KrasG12D/+/LSL-Trp53R172H/+/Pdx1-
Cre/RARE-LacZ mice. Pancreatic tumours, which were predom-
inantly moderately-differentiated and contained abundant desmo-
plastic stroma formed in all mice. There was again a complete
absence of retinoid signalling activity in these tumours and in
precursor lesions despite multiple sectioning and assessment by 2
independent observers, one of whom was a specialist pancreatic
pathologist (Figure 3D, E,F).
Figure 1. RA signalling activity in adult Retinoic Acid Response Element (RARE-LacZ) reporter mouse pancreas showing positive
pancreatic islet (A) and rare positive exocrine cells (B), some of which may represent centro-acinar cells (based on location and
morphology) (C–D).
doi:10.1371/journal.pone.0029075.g001
Retinoid Signalling in PC
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Loss of CRBP1 expression is a common and early event in
pancreatic cancer
Cellular Retinoid Binding Protein 1 (CRBP1), a key regulator of
retinoid signaling is thought to play a significant role in breast
carcinogenesis [16,34]. Preliminary observations also identified
downregulation of CRBP1 transcript levels in PC [35] and PanIN
[36]. As a consequence, we investigated loss of CRBP1 as a
potential cause of diminished retinoid signaling in PC, and a role
in pancreatic carcinogenesis.
In a cohort of 90 patients, immunohistochemistry showed
significant downregulation of CRBP1 protein expression in 70%,
with complete loss of expression in 50% of these (35% of total;
Figure 4A, B, C,D). Loss, or downregulation of CRBP1 expression
occurred early in PC development and was present in 100% of
PanIN-1A and 1B lesions of patients who had aberrant expression
within their cancer (Figure 4E, F). Loss of CRBP1 expression also
occurred in 50% of early precursor lesions (PanIN1A and 1B)
associated with chronic pancreatitis, a known risk factor for PC.
Figure 2. H&E staining of pancreata from RARE-LacZ mice treated with caerulein (A), and subsequent recovery for 2 weeks (B), 4
weeks (C) and 6 weeks (D). RA signalling activity in pancreata from RARE-LacZ mice treated with caerulein (E), and subsequent recovery for 2
weeks (F), 4 weeks (G) and 6 weeks (H). Increased retinoid signaling activity was observed in a significant proportion of acinar cells immediately
following cessation of caerulein treatment (E), with retinoid activity peaking at 2 weeks (F), diminishing at 4 weeks (G) and returning to near normal
levels following 6 weeks of recovery (H).
doi:10.1371/journal.pone.0029075.g002
Retinoid Signalling in PC
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Neither loss, nor downregulation of expression was associated with
patient outcome (Log-Rank P=0.3539; Figure S1). In addition, 4
of the 6 PC cell lines demonstrated loss or downregulation of
CRBP1 expression (Figure 5A and B).
Loss of CRBP1 expression is associated with reversible
promoter hypermethylation
Methylation specific PCR (MSP) and bisulfite genomic sequenc-
ing (BSG) identified CRBP1 promoter hypermethylation in 27.3%
of 33 human PC samples lacking CRBP1 expression in contrast to 5
of 5 matched normal pancreas samples which were not methylated.
CRBP1 promoter hypermethylation was detected in MiaPaCa2
cells (Figure 5C), and treatment with the demethylating agent 5-
AZA alone, or in combination with the HDAC inhibitor TSA,
induced expression of CRBP1 mRNA (Figure 5D). The ability to
reverse CRBP1 silencing pharmacologically presented the potential
opportunity to use retinoids and HDAC inhibitors as combination
therapies to therapeutically target CRBP1.
Downregulation of CRBP1 expression in cell lines and
mouse models
To assess the role of CRBP1 downregulation in pancreatic
carcinogenesis, immortalized Human Pancreatic Ductal Epithelial
cells expressing the mouse ecotropic retroviral receptor (HPDE-EcoR)
were retrovirally transduced with two shRNA constructs targeting
CRBP1 as well as a scrambled control. Cells were then grown in 3D
culture for 20 days. Western blot demonstrated 50% knockdown of
CRBP1 expression (Figure 5E), however, there was no discernible
difference in morphology compared to controls (Figure 5F). In
addition, pancreata from 12 month-old CRBP1 knockout mice [37]
(kindly provided by Prof. Pierre Chambon) revealed no obvious
morphological differences compared to control mice (data not shown).
CRBP1 overexpression in MiaPaCa2 cells
In order to examine the effects of restoration of CRBP1
expression, MiaPaCa2 cells, which normally do not express
CRBP1 were stably transfected to generate several clones
expressing different levels of CRBP1 (low, medium, high and
very high) with no effect on the proliferation rates compared to the
empty vector control (Figure S2A) and did not alter sensitivity to
retinoid therapy when treated with All-trans Retinoic Acid (AtRA)
(Figures S2B and S2C).
Discussion
The emerging role of dysregulated embryonic signaling
pathways such as Notch and Hedgehog [4] is providing
Figure 3. RA signalling activity in DMBA-induced tumours (A–B) and in LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx1-Cre;RARE-LacZ
pancreatic tumours (C–D) and mPanIN lesions (E–F). In tumors from DMBA treated RARE-LacZ mice, a distinct absence of any cells exhibiting
active retinoid signaling was observed (B). In LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx1-Cre;RARE-LacZ pancreatic tumours and precursor lesions, there
was also a complete absence of retinoid signaling activity (D and F respectively).
doi:10.1371/journal.pone.0029075.g003
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opportunities for the development of novel therapeutic strategies
for pancreatic cancer. Retinoid signaling is indispensible for
normal embryonic development, including the formation of the
nascent pancreas [6,7,8]. Our data show that signaling activity in
normal pancreas is restricted to pancreatic islets and rare cells in
the exocrine pancreas, many of which resembled centro-acinar
cells, the putative stem cells of the pancreas. A recent study
identified that cells in the pancreas expressing the RA-synthesising
enzyme, aldehyde dehydrogenase 1 (ALDH1), are centroacinar
cells that exhibit progenitor cell characteristics [38]. This pattern
of activity is similar to the expression of the transcription factor
Pdx1 which is also thought to mark exocrine progenitor or ‘‘stem’’
cells. Functional readouts of in vivo retinoid signaling activity using
reporter mice in our study suggest that augmented signaling plays
a role in pancreatic regeneration after injury. Active signaling,
normally restricted to specific cell types becomes widespread until
differentiation of new exocrine acini is complete. Treatment of
mice with repeated doses of caerulein results in a dramatic increase
in ALDH1-positive cells, which is assumed to represent increased
retinoid signaling [38], further supporting our findings.
Deregulated retinoid signaling has been identified in many
cancer types [11], and although previous studies have identified
aberrant expression of components of retinoid signaling as well as
downstream targets in PC [35,39,40,41,42,43], little was known
concerning retinoid signaling activity. Assessment of retinoid
signaling reporter activity in both chemically induced pancreatic
cancer, and in genetically engineered models in our study
demonstrated a lack of retinoid signaling. Based on these
observations, we hypothesized that a lack of retinoic acid signaling
may impede normal differentiation in response to carcinogenic
stimuli and contribute to pancreatic carcinogenesis, and that
restoration of retinoid signaling may provide a novel therapeutic
option.
As a consequence, we investigated the role of CRBP1, a key
component of retinoid signaling, and thought to play a major role
in breast carcinogenesis [16,34]. We identified loss, or downreg-
ulation of CRBP1 expression (which would potentially confer loss
of retinoid signaling activity) in 70% of pancreatic cancer
specimens, with a high proportion due to promoter methylation.
Loss or downregulation of CRBP1 expression was present in the
earliest precursor lesions of PC, both in association with PC and in
chronic pancreatitis, a risk factor for the development of PC.
However, knockdown of CRBP1 expression in immortalised
pancreatic ductal epithelial cells did not induce transformation.
Similarly, CRBP1 knockout mice did not demonstrate a
pancreatic phenotype at over 12 months of age. In addition,
reintroduction of CRBP1 in PC cells deficient in CRBP1 did not
alter insensitivity to retinoid therapy. Importantly, recent data
Figure 4. CRBP1 expression in (A) normal pancreas, (B) PC positive for CRBP1, (C) PC demonstrating partial loss of CRBP1
expression, (D) PC completely lacking CRBP1 expression, (E) PanIN-1A lesion negative for CRBP1 expression, (F) PanIn-1B (*) lesion
negative for CRBP1 expression with positive adjacent normal ductal epithelium.
doi:10.1371/journal.pone.0029075.g004
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Figure 5. mRNA expression (A) and protein expression (B) of CRBP1 in PC cell lines. (C) CRBP1 methylation status in PC cell lines and (D)
restoration of CRBP1 expression with combination treatment of MiaPaCa2 cells with 5-Aza and TSA. (E) CRBP1 knockdown in stably transfected HPDE-
EcoR cells. (F) HPDE cells grown in 3D demonstrate no change in morphology between siCRBP1 cells and scrambled control.
doi:10.1371/journal.pone.0029075.g005
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suggest that pancreatic stellate cells may play a key role in retinoid
signaling and resistance to retinoid therapy in vivo [44]. This needs
to be taken into consideration, particularly as the data presented
here focused on the pancreatic epithelial component.
In summary, pancreatic injury induces retinoid signaling
activity within the pancreas, which is widespread during injury
and regeneration and potentially plays an important role in this
process. The lack of retinoid signaling activity in mouse models of
pancreatic cancer suggests an important role in pancreatic
carcinogenesis, however, despite the high prevalence of loss of
CRBP1 expression, and its key role in other cancers, there is no
evidence to support that loss of CRBP1 is alone sufficient to alter
retinoid signaling, or induce carcinogenesis in the model systems
used in this study.
Supporting Information
Figure S1 Kaplan-Meier survival curve for CRBP1
expression in PC.
(TIF)
Figure S2 Cell proliferation assay of MiaPaCa2 cells
transfected with different levels of CRBP1 (A). Effect of
retinoid treatment on (B) MiaPaCa2 cells; (C) MiaPaCa2 cells
transfected with CRBP1; and (D) HPDE cells. MiaPaCa2 cells
were resistant to AtRA treatment, despite the re-introduction of
CRBP1, while HPDE cells were sensitive to AtRA treatment.
(TIF)
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